What is the place of conservative management for adult supratentorial low-grade glioma?

  • I. R. Whittle
Part of the Advances and Technical Standards in Neurosurgery book series (NEUROSURGERY, volume 35)


Adult supratentorial low-grade gliomas (LGG) cover a spectrum of neuropathologies that invariably present with seizure disorders. Following neuroradiological diagnosis management strategy will be determined by prognostic indicators such as patient age, lesion size, lesion location, clinical performance status and radiological differential diagnosis. Conservative management, characterised by a “watch and wait” policy, with serial neuroimaging and clinical observation, may form an integral part of overall Multi-Disciplinary Team management strategy in many patients. Conservative management may include the periods following radiological diagnosis to primary surgery, and from the time of surgery to timing of radiotherapy or chemotherapy. Results from randomised controlled clinical trials in LGG, recent findings following microsurgical excision, findings from serial observations using volumetric MRI, and recent findings following chemotherapy and tumour genotyping have helped in defining the place of conservative management in individual cases. These recent findings have moved conservative management from a ‘controversial’ legacy of a bygone era to a more objectively based coherent management component that is understood by both medical and surgical neuro-oncologists. However there is still no evidence from randomised controlled trials to either support or indict the role of conservative management, prior to primary intervention, in LGG. Informing patients of the uncertainties in both interventional strategies and the place of conservative management in LGG is essential in optimising patient outcomes and satisfaction.


Low-grade glioma astrocytoma oligodendroglioma MRI clinical trials watch and wait 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, Wara W, MacDonald D, Stitt L, Cairncross JG (1999) Pretreatment factors predict overall survival for patients with lowgrade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys 45(4): 923–29PubMedGoogle Scholar
  2. 2.
    Berger MS, Deliganis AV, Dobbins J, Keles GE (1994) The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74(6): 1784–91CrossRefPubMedGoogle Scholar
  3. 3.
    Cairncross JG, Laperriere NJ (1989) Low-grade glioma. To treat or not to treat? Arch Neurol 46(11): 1238–39PubMedGoogle Scholar
  4. 4.
    Chaichana KL, McGirt MJ, Niranjan A, Olivi A, Burger PC, Quinones-Hinojosa A (2009) Prognostic significance of contrast-enhancing low-grade gliomas in adults and a review of the literature. Neurol Res [Epub ahead of print]Google Scholar
  5. 5.
    Chang EF, Smith JS, Chang SM, Lamborn KR, Prados MD, Butowski N, Barbaro NM, Parsa AT, Berger MS, McDermott MM (2008) Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg 109(5): 817–24CrossRefPubMedGoogle Scholar
  6. 6.
    Danchaivijitr N, Waldman AD, Tozer DJ, Benton CE, Brasil Caseiras G, Tofts PS, Rees JH, Jäger HR (2008) Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? Radiology 247(1): 170–78CrossRefPubMedGoogle Scholar
  7. 7.
    Duffau H (2006) Management of low-grade gliomas. Rev Prat [Article in French] 56(16): 1771–77Google Scholar
  8. 8.
    Duffau H, Capelle L, Denvil D, Sichez N, Gatignol P, Lopes M, Mitchell MC, Sichez JP, Van Effenterre R (2003) Functional recovery after surgical resection of low-grade gliomas in eloquent brain: hypothesis of brain compensation. J Neurol Neurosurg Psychiatry 74(7): 901–07CrossRefPubMedGoogle Scholar
  9. 9.
    Duffau H, Lopes M, Arthuis F, Bitar A, Sichez JP, Van Effenterre R, Capelle L (2005) Contribution of intraoperative electrical stimulations in surgery of low-grade gliomas: a comparative study between two series without (1985-96) and with (1996-2003) functional mapping in the same institution. J Neurol Neurosurg Psychiatry 76(6): 845–51CrossRefPubMedGoogle Scholar
  10. 10.
    Feigenberg SJ, Amdur RJ, Morris CG, Mendenhall WM, Marcus RB Jr, Friedman WA (2003) Oligodendroglioma: does deferring treatment compromise outcome? Am J Clin Oncol 26(3): e60–66CrossRefPubMedGoogle Scholar
  11. 11.
    Guidelines and Outcomes Committee of the American Association of Neurological Surgeons (AANS) (1998) Practice parameters in adults with suspected or known supratentorial nooptic pathway low-grade glioma. Neurosurg Focus 4(6): 10CrossRefGoogle Scholar
  12. 12.
    Guillevin R, Menuel C, Duffau H, Kujas M, Capelle L, Aubert A, Taillibert S, Idbaih A, Pallud J, Demarco G, Costalat R, Hoang-Xuan K, Chiras J, Vallèe JN (2008) Proton magnetic resonance spectroscopy predicts proliferative activity in diffuse low-grade gliomas. J Neurooncol 87(2): 181–87CrossRefPubMedGoogle Scholar
  13. 13.
    Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, Polivka M, Crinière E, Marie Y, Mokhtari K, Carpentier AF, Laigle F, Simon JM, Cornu P, Broët P, Sanson M, Delattre JY (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22(15): 3133–38CrossRefPubMedGoogle Scholar
  14. 14.
    Janny P, Cure H, Mohr M, Heldt N, Kwiatkowski F, Lemaire JJ, Plagne R, Rozan R (1994) Low grade supratentorial astrocytomas. Management and prognostic factors. Cancer 73(7): 1937–45CrossRefPubMedGoogle Scholar
  15. 15.
    Jenkinson MD, du Plessis DG, Smith TS, Joyce KA, Warnke PC, Walker C (2006) Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 129(Pt 7): 1884–91CrossRefPubMedGoogle Scholar
  16. 16.
    Karim AB, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O, Darcel F, Stenning S, Pierart M, Van Glabbeke M (2002) Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study (22845) with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 52(2): 316–24PubMedGoogle Scholar
  17. 17.
    Keles GE, Lamborn KR, Berger MS (2001) Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 95(5): 735–45CrossRefPubMedGoogle Scholar
  18. 18.
    Kortmann RD, Jeremic B, Weller M, Lutterbach J, Paulsen F, Bamberg M (2004) Immediate postoperative radiotherapy or “watch and wait” in the management of adult low-grade glioma? Strahlenther Onkol 180(7): 408–18CrossRefPubMedGoogle Scholar
  19. 19.
    Kujas M, Lejeune J, Benouaich-Amiel A, Crinière E, Laigle-Donadey F, Marie Y, Mokhtari K, Polivka M, Bernier M, Chretien F, Couvelard A, Capelle L, Duffau H, Cornu P, Broët P, Thillet J, Carpentier AF, Sanson M, Hoang-Xuan K, Delattre JY (2005) Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Ann Neurol 58(2): 322–26CrossRefPubMedGoogle Scholar
  20. 20.
    Lang FF, Olansen NE, Demonte F, Gokaslan ZL, et al. (2001) Surgical resection of intrinsic insula tumours: complication avoidance. J Neurosurg 95: 638–50CrossRefPubMedGoogle Scholar
  21. 21.
    Law M, Oh S, Babb JS, Wang E, Inglese M, Zagzag D, Knopp EA, Johnson G (2006) Lowgrade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging — prediction of patient clinical response. Radiology 238(2): 658–67CrossRefPubMedGoogle Scholar
  22. 22.
    Mandonnet E, Delattre JY, Tanguy ML, Swanson KR, Carpentier AF, Duffau H, Cornu P, Van Effenterre R, Alvord EC Jr, Capelle L (2003) Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 53(4): 524–28CrossRefPubMedGoogle Scholar
  23. 23.
    Mandonnet E, Pallud J, Clatz O, Taillandier L, Konukoglu E, Duffau H, Capelle L (2008) Computational modeling of the WHO grade II glioma dynamics: principles and applications to management paradigm. Neurosurg Rev 31(3): 263–69 [Epub 2008 Feb 26]CrossRefPubMedGoogle Scholar
  24. 24.
    Meyers CA, Brown PD (2006) Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 24(8): 1305–09CrossRefPubMedGoogle Scholar
  25. 25.
    Meyer FB, Bates LM, Goerss SJ, Friedman JA, Windschitl WL, Duffy JR, Perkins WJ, O’Neill BP (2001) Awake craniotomy for aggressive resection of primary gliomas located in eloquent brain. Mayo Clin Proc 76(7): 677–87CrossRefPubMedGoogle Scholar
  26. 26.
    Papagikos MA, Shaw EG, Stieber VW (2005) Lessons learned from randomised clinical trials in adult low-grade glioma. Lancet Oncol 6(4): 240–44CrossRefPubMedGoogle Scholar
  27. 27.
    Pallud J, Capelle L, Taillandier L, Fontaine D, Mandonnet E, Guillevin R, Bauchet L, Peruzzi P, Laigle-Donadey F, Kujas M, Guyotat J, Baron MH, Mokhtari K, Duffau H (2008) Prognostic Significance of Imaging Contrast Enhancement for WHO grade II Gliomas. Neuro Oncol [Epub ahead of print]Google Scholar
  28. 28.
    Pallud J, Mandonnet E, Duffau H, Kujas M, Guillevin R, Galanaud D, Taillandier L, Capelle L (2006) Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol 60(3): 380–83CrossRefPubMedGoogle Scholar
  29. 29.
    Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB; European Organization for Research and Treatment of Cancer Brain Tumor Cooperative Group; European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20(8): 2076–84CrossRefPubMedGoogle Scholar
  30. 30.
    Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE 2nd, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, Stafford-Fox V, Zaknoen S, Friedman HS (2003) Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21(4): 646–51CrossRefPubMedGoogle Scholar
  31. 31.
    Recht LD, Lew R, Smith TW (1992) Suspected low-grade glioma: is deferring treatment safe? Ann Neurol 31(4): 431–36CrossRefPubMedGoogle Scholar
  32. 32.
    Rees J, Watt H, Jäager HR, Benton C, Tozer D, Tofts P (2008) Waldman volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation. Eur J Radiol [Epub ahead of print]Google Scholar
  33. 33.
    Reijneveld JC, van der Grond J, Ramos LM, Bromberg JE, Taphoorn MJ (2005) Proton MRS imaging in the follow-up of patients with uspected low-grade gliomas. Neuroradiology 47(12): 887–91 [Epub 2005 Aug 20]CrossRefPubMedGoogle Scholar
  34. 34.
    Reijneveld JC, Sitskoorn MM, Klein M, Nuyen J, Taphoorn MJ (2001) Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas. Neurology 56(5): 618–23PubMedGoogle Scholar
  35. 35.
    Ricard D, Kaloshi G, Amiel-Benouaich A, Lejeune J, Marie Y, Mandonnet E, Kujas M, Mokhtari K, Taillibert S, Laigle-Donadey F, Carpentier AF, Omuro A, Capelle L, Duffau H, Cornu P, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY (2007) Dynamic history of lowgrade gliomas before and after temozolomide treatment. Ann Neurol 61(5): 484–90CrossRefPubMedGoogle Scholar
  36. 36.
    Schneider JP, Schulz T, Schmidt F, Dietrich J, Lieberenz S, Trantakis C, Seifert V, Kellermann S, Schober R, Schaffranietz L, Laufer M, Kahn T (2001) Gross-total surgery of supratentorial low-grade gliomas under intraoperative MR guidance. Am J Neuroradiol 22(1): 89–98PubMedGoogle Scholar
  37. 37.
    Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA (2002) How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 59(6): 947–49PubMedGoogle Scholar
  38. 38.
    Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS (2008) Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26(8): 1338–45CrossRefPubMedGoogle Scholar
  39. 39.
    Van den Bent MJ (2003) Low-grade gliomas: how should patients be managed? In: Williams C (ed) Evidence based oncology. BMJ Publishing, London, pp 561–64CrossRefGoogle Scholar
  40. 40.
    van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C (1998) Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry 64(5): 581–87CrossRefPubMedGoogle Scholar
  41. 41.
    Vecht CJ (1993) Effect of age on treatment decisions in low-grade glioma. J Neurol Neurosurg Psychiatry 56(12): 1259–64CrossRefPubMedGoogle Scholar
  42. 42.
    Wessels PH, Weber WE, Raven G, Ramaekers FC, Hopman AH, Twijnstra A (2003) Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol 2(7): 395–403CrossRefPubMedGoogle Scholar
  43. 43.
    Whittle IR 2004. The dilemma of low-grade glioma. J Neurol Neurosurg Psychiatry 75 (Suppl 2): ii31–36Google Scholar
  44. 44.
    Whittle IR, Borthwick S, Haq N (2003) Brain dysfunction following ‘awake’ craniotomy, brain mapping and resection of glioma. Br J Neurosurg 17ai](2): 130–37CrossRefPubMedGoogle Scholar
  45. 45.
    Yaşargil MG, von Ammon K, Cavazos E, Doczi T, Reeves JD, Roth P (1992) Tumours of the limbic and paralimbic systems. Acta Neurochir (Wien) 118(1–2): 40–52CrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2010

Authors and Affiliations

  • I. R. Whittle
    • 1
  1. 1.Department of Clinical NeurosciencesUniversity of Edinburgh, Western General HospitalEdinburghUK

Personalised recommendations